London: Danish pharmaceutical giant Novo Nordisk announced a partnership with OpenAI to integrate artificial intelligence across its operations, aiming to strengthen its position in the highly competitive weight-loss drug market, where it faces growing competition from Eli Lilly.
The company, known for weight-loss drugs Wegovy and Ozempic, said that the collaboration will leverage OpenAI’s technology to analyse complex datasets, identify potential drug candidates, and enhance efficiency across manufacturing, supply chains, distribution, and commercial operations.
Pharmaceutical firms are increasingly adopting AI to streamline time-consuming aspects of drug development, such as identifying clinical trial participants, selecting trial sites, and preparing regulatory submissions.
Novo Nordisk and @OpenAI partner to transform how medicines are discovered and delivered. Read more here:https://t.co/JJoSqHmOzA pic.twitter.com/pZeoWz1Eld
— Novo Nordisk (@novonordisk) April 14, 2026
However, industry leaders acknowledge that AI has yet to fully deliver breakthroughs in discovering entirely new molecules. Novo Nordisk is seeking innovative strategies to regain momentum in the obesity drug market, especially as Eli Lilly continues to gain ground.
The US-based company recently secured approval for its weight-loss pill, Foundayo, intensifying competition following Novo’s launch of an oral version of Wegovy earlier this year. Analysts predict the global weight-loss drug market could generate over $100 billion annually in the coming decade.
While financial details of the agreement were not disclosed, Novo Nordisk confirmed that pilot programmes will begin across research and development, manufacturing, and commercial functions, with full implementation targeted by the end of 2026.
The partnership will also focus on upskilling Novo Nordisk’s global workforce, with OpenAI supporting AI training initiatives to improve digital literacy and productivity across departments.
CEO Mike Doustdar emphasised that the initiative is designed to enhance, not replace, human expertise. Doustdar stated that the goal is to ‘supercharge’ scientists by enabling them to work more efficiently, rather than reducing staff.
However, he noted that improved productivity could slow the pace of future hiring. The company had previously announced a restructuring plan that resulted in 9,000 job cuts shortly after Doustdar assumed leadership.
Sam Altman highlighted the broader impact of the collaboration, stating that AI has the potential to transform life sciences by accelerating innovation and improving patient outcomes. Altman added that the partnership would help Novo Nordisk advance scientific discovery, optimise global operations, and shape the future of healthcare.
Novo Nordisk also confirmed that the partnership includes strict data protection measures, governance frameworks, and human oversight, building on its existing AI collaborations with technology partners and research institutions.
MOST READ | England tightens school meals to improve child health
